Novo Nordisk's shares plummeted on Tuesday, falling as much as 14% after the company announced a decline in sales and profit growth for 2026.
The company pointed to lower prices in the U.S. and the loss of exclusivity for its popular drugs, Wegovy and Ozempic, in several international markets, including China, Brazil, and Canada.
For the upcoming year, Novo Nordisk expects sales and operating profits to decline between 5% and 13% at constant exchange rates.
This forecast is significantly worse than what analysts had anticipated. The company is currently facing challenges in its largest market, the U.S., which is impacting its overall performance.
Despite the ominous outlook for 2026, Novo Nordisk reported a 10% increase in sales and a 6% increase in operating profit for 2025.
In the fourth quarter, the company saw net sales total 79.1 billion Danish kroner, which is equivalent to about $12.5 billion, slightly exceeding the analysts' expectations of 77.8 billion kroner.
In the fourth quarter, Novo Nordisk's best-selling drug, Ozempic, generated sales of 31.8 billion kroner, marking a 1% increase compared to the same period last year.
Additionally, Wegovy sales reached 21.9 billion kroner, reflecting a 17% increase year-over-year.
With increasing competition from Eli Lilly's weight-loss drug, tirzepatide, Novo Nordisk is striving to regain market share in the U.S. market.
The company is optimistic about launching Wegovy in more countries in 2026 and introducing a higher 7.2 mg dose in several markets.
Moving forward, Novo Nordisk is focusing on the U.S. launch of the oral version of Wegovy. CEO Mike Doustdar expressed confidence in the drug's potential to drive volume growth in the coming years, despite the current pricing pressures and competition.
Investors remain cautious, however, as they await updates on Novo’s strategy to navigate the shifting market dynamics.
